Obesity-Related Disorders in Türkiye: A Multi Center, Retrospective, Cross-Sectional Analysis from the OBREDI-TR Study
Abstract
:1. Introduction
2. Material and Methods
2.1. Patient Selection
2.2. Data Collection
Diabetes mellitus [16] | HBa1c of greater than or equal to 6.5% Fasting glucose greater than or equal to 126 mg/dL Random blood glucose of greater than or equal to 200 mg/dL with any symptom related to diabetes Oral Glucose Tolerance Test: Two-hour blood glucose of greater than or equal to 200 mg/dL or use of antidiabetic drugs with a previously confirmed diagnosis of T2DM based on the above criteria |
Hypertension [17] | As defined by ESH 2024, equal or above 140/90 mmHg arterial blood pressure or use of anti-hypertensive drugs previously with a previously confirmed diagnosis of HT based on the above criteria |
Dyslipidemia [18] | LDL over 70 mg/dL and/or HDL under 50 mg/dL and/or total cholesterol over 200 mg/dL and/or triglycerides above 150 mg/dL or taking an anti-hyperlipidemic drug. (Sensitivity analysis performed using LDL ≥ 130 mg/dL for comparison in Table 2). |
Coronary artery disease [19] | Previous MI, coronary bypass surgery history, stent, or stenosis confirmed by coronary angiography |
Obstructive pulmonary disorders [20] | Asthma or COPD confirmed by RFT |
Obstructive sleep apnea syndrome [21] | Confirmed diagnosis with polysomnography |
Fatty Liver Disease [22] | Fatty deposits determined by non-invasive imaging (USG/Elastography/CT/MRI) |
Aegean (n = 1139) | Marmara (n = 3436) | Central Anatolia (n = 1314) | Black Sea (n = 797) | Eastern Anatolia (n = 452) | Southeastern Anatolia (n = 1824) | Mediterranean (n = 1159) | FDR-Adjusted p-Value | |
---|---|---|---|---|---|---|---|---|
DM | 509(44.7) | 1272(37.0) | 294(22.4) | 316(39.6) | 154(34.1) | 535(29.3) | 399(34.4) | <0.001 |
HT | 714(62.7) | 1852(53.9) | 596(45.4) | 512(64.2) | 188(41.6) | 879(48.2) | 744(64.2) | <0.001 |
DL70 | 1088(95.5) | 2502(72.8) | 1002(76.3) | 591(74.2) | 416(92.0) | 1410(77.3) | 882(76.1) | <0.001 |
DL130 | 392(34.4) | 657(19.1) | 371(28.2) | 232(29.1) | 134(29.6) | 440(24.1) | 258(22.3) | <0.001 |
OPD | 186(16.3) | 233(6.8) | 168(12.8) | 55(6.9) | 42(9.3) | 181(9.9) | 89(6.8) | <0.001 |
CAD | 152(13.3) | 408(11.9) | 107(8.1) | 81(10.2) | 83(18.4) | 218(12.0) | 116(11.9) | <0.001 |
OSAS | 72(6.3) | 126(3.7) | 68(5.2) | 15(1.9) | 10(2.2) | 161(8.8) | 50(3.7) | <0.001 |
FLD | 640(56.2) | 1802(52.4) | 336(25.6) | 266(33.4) | 176(38.9) | 514(28.2) | 459(39.6) | <0.001 |
2.3. Statistics
3. Results
Multivariate Analysis of Risk Factors for Comorbidities
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Yumuk, V.; Tsigos, C.; Fried, M.; SchindLer, K.; Busetto, L.; Micic, D.; Toplak, H. European Guidelines for Obesity Management in Adults. Obes. Facts 2015, 8, 402–424. [Google Scholar] [CrossRef] [PubMed]
- Gutiérrez-Cuevas, J.; Santos, A.; Armendariz-Borunda, J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int. J. Mol. Sci. 2021, 22, 11629. [Google Scholar] [CrossRef] [PubMed]
- WHO. Obesity and Overweight. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 1 January 2025).
- WHO. World Obesity Atlas; WHO: Geneva, Switzerland, 2024.
- WHO. WHO European Regional Obesity Report 2022. Available online: https://www.who.int/europe/publications/i/item/9789289057738 (accessed on 1 January 2025).
- Aksoy, M.; Kazkondu, I. Türkiye’de Yiyecek Seçiminin Bölgelere Göre Farklılaşması** (Variation of Food Choices According to Regions in Turkey). J. Tour. Gastron. Stud. 2023, 8, 1306–1333. [Google Scholar] [CrossRef]
- Türkiye, M.o.H.o.t.R.o. OBEZİTE VE DİYABET KLİNİK REHBERİ; 2017. Available online: https://hsgm.saglik.gov.tr/depo/birimler/saglikli-beslenme-ve-hareketli-hayat-db/Dokumanlar/Rehberler/Obezite-ve-Diyabet-Klinik-Rehberi.pdf (accessed on 28 March 2025).
- Bjørndal, B.; Burri, L.; Staalesen, V.; Skorve, J.; Berge, R.K. Different adipose depots: Their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J. Obes. 2011, 2011, 490650. [Google Scholar] [CrossRef]
- Ibrahim, M.M. Subcutaneous and visceral adipose tissue: Structural and functional differences. Obes. Rev. 2010, 11, 11–18. [Google Scholar] [CrossRef]
- Heymsfield, S.B.; Wadden, T.A. Mechanisms, Pathophysiology, and Management of Obesity. N. Engl. J. Med. 2017, 376, 254–266. [Google Scholar] [CrossRef]
- GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1223–1249. [Google Scholar] [CrossRef]
- WHO. The Global Health Observatory; WHO: Geneva, Switzerland. Available online: https://www.who.int/data/gho (accessed on 28 March 2025).
- IDF. IDF Diabetes Atlas; IDF: Brussels, Belgium, 2021. [Google Scholar]
- Peppard, P.E.; Young, T.; Barnet, J.H.; Palta, M.; Hagen, E.W.; Hla, K.M. Increased prevalence of sleep-disordered breathing in adults. Am. J. Epidemiol. 2013, 177, 1006–1014. [Google Scholar] [CrossRef]
- Wharton, S.; Lau, D.C.W.; Vallis, M.; Sharma, A.M.; Biertho, L.; Campbell-Scherer, D.; Adamo, K.; Alberga, A.; Bell, R.; Boulé, N.; et al. Obesity in adults: A clinical practice guideline. Can. Med. Assoc. J. 2020, 192, E875–E891. [Google Scholar] [CrossRef]
- Marx, N.; Federici, M.; Schütt, K.; Müller-Wieland, D.; Ajjan, R.A.; Antunes, M.J.; Christodorescu, R.M.; Crawford, C.; Di Angelantonio, E.; Eliasson, B.; et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur. Heart J. 2023, 44, 4043–4140. [Google Scholar] [CrossRef]
- Kreutz, R.; Brunström, M.; Burnier, M.; Grassi, G.; Januszewicz, A.; Muiesan, M.L.; Tsioufis, K.; de Pinho, R.M.; Albini, F.L.; Boivin, J.-M.; et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur. J. Intern. Med. 2024, 126, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 2019, 41, 111–188. [Google Scholar] [CrossRef]
- McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021, 42, 4901. [Google Scholar] [CrossRef] [PubMed]
- Agustí, A.; Celli, B.R.; Criner, G.J.; Halpin, D.; Anzueto, A.; Barnes, P.; Bourbeau, J.; Han, M.K.; Martinez, F.J.; Montes de Oca, M.; et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 2023, 207, 819–837. [Google Scholar] [CrossRef]
- Berry, R.B.; Budhiraja, R.; Gottlieb, D.J.; Gozal, D.; Iber, C.; Kapur, V.K.; Marcus, C.L.; Mehra, R.; Parthasarathy, S.; Quan, S.F.; et al. Rules for scoring respiratory events in sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J. Clin. Sleep. Med. 2012, 8, 597–619. [Google Scholar] [CrossRef] [PubMed]
- EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1388–1402. [CrossRef]
- Seravalle, G.; Grassi, G. Obesity and hypertension. Pharmacol. Res. 2017, 122, 1–7. [Google Scholar] [CrossRef]
- Rohm, T.V.; Meier, D.T.; Olefsky, J.M.; Donath, M.Y. Inflammation in obesity, diabetes, and related disorders. Immunity 2022, 55, 31–55. [Google Scholar] [CrossRef]
- Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet 2005, 365, 1415–1428. [Google Scholar] [CrossRef]
- Landsberg, L.; Aronne, L.J.; Beilin, L.J.; Burke, V.; Igel, L.I.; Lloyd-Jones, D.; Sowers, J. Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment: A position paper of The Obesity Society and the American Society of Hypertension. J. Clin. Hypertens. 2013, 15, 14–33. [Google Scholar] [CrossRef]
- Fantin, F.; Giani, A.; Zoico, E.; Rossi, A.P.; Mazzali, G.; Zamboni, M. Weight loss and hypertension in obese subjects. Nutrients 2019, 11, 1667. [Google Scholar] [CrossRef] [PubMed]
- Altun, B.; Arici, M.; Nergizoglu, G.; Derici, Ü.; Karatan, O.; Turgan, Ç.; Sindel, S.; Erbay, B.; Hasanoglu, E.; Çaglar, S.; et al. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J. Hypertens. 2005, 23, 1817–1823. [Google Scholar] [CrossRef]
- Satman, I.; Omer, B.; Tutuncu, Y.; Kalaca, S.; Gedik, S.; Dinccag, N.; Karsidag, K.; Genc, S.; Telci, A.; Canbaz, B.; et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur. J. Epidemiol. 2013, 28, 169–180. [Google Scholar] [CrossRef]
- Oral, A.; Küçük, C.; Köse, M. Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study. J. Clin. Med. 2024, 13, 6121. [Google Scholar] [CrossRef] [PubMed]
- Neupane, S.; Florkowski, W.J.; Dhakal, U.; Dhakal, C. Regional disparities in type 2 diabetes prevalence and associated risk factors in the United States. Diabetes Obes. Metab. 2024, 26, 4776–4782. [Google Scholar] [CrossRef]
- Kayıkçıoğlu, M.; Tokgözoğlu, L.; Kılıçkap, M.; Göksülük, H.; Karaaslan, D.; Özer, N.; Abacı, A.; Yılmaz, M.B.; Barçın, C.; Ateş, K.; et al. Data on prevalence of dyslipidemia and lipid values in Turkey: Systematic review and meta-analysis of epidemiological studies on cardiovascular risk factors. Turk. Kardiyol. Dern. Ars. 2018, 46, 556–574. [Google Scholar] [CrossRef] [PubMed]
- Willi, C.; Bodenmann, P.; Ghali, W.A.; Faris, P.D.; Cornuz, J. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2007, 298, 2654–2664. [Google Scholar] [CrossRef]
- Lonardo, A.; Nascimbeni, F.; Ballestri, S.; Fairweather, D.; Win, S.; Than, T.A.; Abdelmalek, M.F.; Suzuki, A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology 2019, 70, 1457–1469. [Google Scholar] [CrossRef]
- Blüher, M. Metabolically Healthy Obesity. Endocr. Rev. 2020, 41, bnaa004. [Google Scholar] [CrossRef]
- Society, T.E.A.M. Turkish Endocrinology and Metabolism Society. Obesity Diagnosis and Treatment Guideline (2023). Available online: https://file.temd.org.tr/Uploads/publications/guides/documents/obezitetanitedavikilavizu-2024.pdf (accessed on 28 March 2025).
- Health, G.D.o.P. Turkish Ministry of Health. Turkey Nutrition and Health Survey 2017 (TBSA-2017). Available online: https://hsgm.saglik.gov.tr/tr/obezite (accessed on 28 March 2025).
- Jakubiak, G.K.; Pawlas, N.; Morawiecka-Pietrzak, M.; Starzak, M.; Stanek, A.; Cieślar, G. Retrospective Cross-Sectional Study of the Relationship of Thyroid Volume and Function with Anthropometric Measurements, Body Composition Analysis Parameters, and the Diagnosis of Metabolic Syndrome in Euthyroid People Aged 18–65. Medicina 2024, 60, 1080. [Google Scholar] [CrossRef]
- Şahintürk, Y.; Köker, G.; Koca, N.; Sümbül, H.E.; Demir, İ.; Keskin, H.; Yaylacı, S.; Solmaz, İ.; Açmaz, B.; Yıldız, H.; et al. Metabolic Dysfunction-Associated Fatty Liver Disease and Fibrosis Status in Patients with Type 2 Diabetes Treated at Internal Medicine Clinics: Türkiye DAHUDER Awareness of Fatty Liver Disease (TR-DAFLD) Study. Turk. J. Gastroenterol. 2024, 35, 643–650. [Google Scholar] [CrossRef] [PubMed]
Age (year) | 45.20 ± 13.92 |
Female sex n (%) | 7222 |
Height (cm) | 163.90 ± 9.41 |
Weight (kg) | 100.15 ± 18.08 |
Body mass index (BMI) (kg/m2) | 37.24 ± 6.04 |
Systolic BP (mmHg) | 134.17 ± 27.45 |
Diastolic BP(mmHg) | 80.88 ± 8.23 |
Smoking status | |
Smoker n (%) | 3146(31.08) |
Ex-smoker n (%) | 1191(11.76) |
Non-smoker n (%) | 5884(58.13) |
Comorbidity | Age | BMI | Female | Ex-Smoker | Smoker | |
---|---|---|---|---|---|---|
DM | OR | 1.01 | 1.00 | 0.94 | 1.38 | 0.96 |
CI (95%) | (1.01–1.02) | (0.99–1.00) | (0.86–1.03) | (1.21–1.58) | (0.87–1.05) | |
p-value | p = 0.000 | p = 0.295 | p = 0.218 | p = 0.000 | p = 0.372 | |
HT | OR | 1.09 | 0.99 | 1.04 | 1.50 | 0.97 |
CI (95%) | (1.08–1.09) | (0.99–1.00) | (0.94–1.15) | (1.29–1.74) | (0.88–1.07) | |
p-value | p = 0.000 | p = 0.131 | p = 0.434 | p = 0.000 | p = 0.564 | |
DL | OR | 1.01 | 1.00 | 0.99 | 1.40 | 1.73 |
CI (95%) | (1.00–1.01) | (0.99–1.01) | (0.89–1.11) | (1.19–1.65) | (1.55–1.94) | |
p-value | p = 0.000 | p = 0.636 | p = 0.911 | p = 0.000 | p = 0.000 | |
CAD | OR | 1.01 | 1.00 | 1.11 | 2.38 | 1.45 |
CI (95%) | (1.00–1.01) | (0.99–1.01) | (0.96–1.28) | (1.99–2.83) | (1.26–1.67) | |
p-value | p = 0.030 | p = 0.495 | p = 0.145 | p = 0.000 | p = 0.000 | |
OPD | OR | 1.02 | 1.00 | 0.90 | 2.05 | 1.26 |
CI (95%) | (1.02–1.03) | (0.99–1.01) | (0.77–1.04) | (1.69–2.49) | (1.08–1.47) | |
p-value | p = 0.000 | p = 0.755 | p = 0.166 | p = 0.000 | p = 0.003 | |
OSAS | OR | 1.03 | 1.00 | 0.88 | 2.16 | 1.71 |
CI (95%) | (1.02–1.04) | (0.98–1.02) | (0.72–1.07) | (1.66–2.81) | (1.40–2.10) | |
p-value | p = 0.000 | p = 0.984 | p = 0.205 | p = 0.000 | p = 0.000 | |
FLD | OR | 1.03 | 1.00 | 0.99 | 1.21 | 1.43 |
CI (95%) | (1.02–1.03) | (0.99–1.01) | (0.86–1.14) | (0.99–1.49) | (1.24–1.66) | |
p-value | p = 0.000 | p = 0.797 | p = 0.911 | p = 0.067 | p = 0.000 |
Comorbidity | <30 | 30–44 | 45–59 | 60+ | p-Value |
---|---|---|---|---|---|
DM | 27.9% | 33.1% | 36.4% | 38.8% | <0.001 |
HT | 31.2% | 39.0% | 57.0% | 97.8% | <0.001 |
DL | 77.9% | 75.3% | 78.9% | 81.5% | <0.001 |
CAD | 8.9% | 13.3% | 11.2% | 10.9% | <0.001 |
OPD | 5.8% | 7.8% | 10.4% | 13.9% | <0.001 |
OSAS | 2.0% | 3.9% | 5.8% | 7.9% | <0.001 |
FLD | 65.5% | 74.8% | 76.8% | 81.6% | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Oral, A.; Solmaz, I.; Koca, N.; Topaloglu, U.S.; Demir, I.; Dundar, A.; Kirik, A.; Basci, O.K.; Sen, H.; Binnetoglu, E.; et al. Obesity-Related Disorders in Türkiye: A Multi Center, Retrospective, Cross-Sectional Analysis from the OBREDI-TR Study. J. Clin. Med. 2025, 14, 2680. https://doi.org/10.3390/jcm14082680
Oral A, Solmaz I, Koca N, Topaloglu US, Demir I, Dundar A, Kirik A, Basci OK, Sen H, Binnetoglu E, et al. Obesity-Related Disorders in Türkiye: A Multi Center, Retrospective, Cross-Sectional Analysis from the OBREDI-TR Study. Journal of Clinical Medicine. 2025; 14(8):2680. https://doi.org/10.3390/jcm14082680
Chicago/Turabian StyleOral, Alihan, Ihsan Solmaz, Nizameddin Koca, Ulas Serkan Topaloglu, Ismail Demir, Ahmet Dundar, Ali Kirik, Ozge Kama Basci, Hacer Sen, Emine Binnetoglu, and et al. 2025. "Obesity-Related Disorders in Türkiye: A Multi Center, Retrospective, Cross-Sectional Analysis from the OBREDI-TR Study" Journal of Clinical Medicine 14, no. 8: 2680. https://doi.org/10.3390/jcm14082680
APA StyleOral, A., Solmaz, I., Koca, N., Topaloglu, U. S., Demir, I., Dundar, A., Kirik, A., Basci, O. K., Sen, H., Binnetoglu, E., Okuroglu, N., Aydin, A., Kaya, Z. I., Yildiz, H., Acet, A., Tazegul, G., Sozel, H., Ozudogru, O., Issever, K., ... Uyar, S. (2025). Obesity-Related Disorders in Türkiye: A Multi Center, Retrospective, Cross-Sectional Analysis from the OBREDI-TR Study. Journal of Clinical Medicine, 14(8), 2680. https://doi.org/10.3390/jcm14082680